Contrave vs Zepbound: Mechanism, Efficacy, and Which One Works for Different Patient Types

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Contrave (naltrexone-bupropion) acts centrally on brain appetite circuits and produces 5-9% total body weight loss over 56 weeks, while Zepbound (tirzepatide) acts peripherally on GLP-1/GIP receptors and produces 15-21% weight loss over 72 weeks.
• Contrave has zero GI side effects in most patients but carries seizure and blood pressure risks; Zepbound causes nausea in 30-40% during titration but has minimal neuropsychiatric effects.
• Contrave works best for patients with binge-eating patterns or emotional eating; Zepbound works best for patients with high baseline appetite and insulin resistance.
• No head-to-head trial exists, but indirect comparison across SURMOUNT-1 (tirzepatide) and COR-I/COR-II (naltrexone-bupropion) shows tirzepatide produces roughly 2.5x the weight loss at 1 year.

Direct answer (40-60 words)

Contrave is a combination of naltrexone (an opioid antagonist) and bupropion (an antidepressant) that reduces appetite through brain reward pathways. Zepbound is tirzepatide, a GLP-1/GIP receptor agonist that slows gastric emptying and suppresses appetite hormonally. Zepbound produces significantly greater weight loss (15-21% vs 5-9%) but has higher GI side effect rates. The mechanisms do not overlap.

Table of contents

1. The mechanism difference: central vs peripheral appetite suppression
2. Head-to-head efficacy: what the indirect comparison shows
3. Side effect profiles: neuropsychiatric vs gastrointestinal
4. The patient-type framework: who responds to which medication
5. What most articles get wrong about Contrave's mechanism
6. Cost and access: insurance coverage patterns in 2026
7. The combination question: can you take both together?
8. Contraindications: who cannot take each medication
9. The clinical pattern we see in patients switching between the two
10. When Contrave is the better choice despite lower efficacy
11. FAQ
12. Sources

The mechanism difference: central vs peripheral appetite suppression

Contrave and Zepbound suppress appetite through completely non-overlapping pathways. Understanding the difference explains why some patients respond dramatically to one and not at all to the other.

Contrave's central mechanism:

Contrave combines naltrexone 8 mg and bupropion 90 mg per tablet (maintenance dose is two tablets twice daily). The combination acts on two brain regions:

1. The hypothalamic POMC pathway. Bupropion stimulates pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus. POMC neurons release alpha-melanocyte-stimulating hormone (α-MSH), which binds to MC4 receptors and suppresses appetite. Naltrexone blocks auto-inhibitory opioid feedback on POMC neurons, amplifying the bupropion effect.

1. The mesolimbic reward system. Bupropion increases dopamine and norepinephrine in the nucleus accumbens and ventral tegmental area. Naltrexone blocks mu-opioid receptors in the same regions. The combination reduces the rewarding value of food, particularly high-fat and high-sugar foods that activate opioid reward pathways.

The result is reduced food cravings, reduced reward from eating, and modest appetite suppression. Contrave does not slow gastric emptying, does not affect incretin hormones, and does not directly affect insulin secretion.

Zepbound's peripheral mechanism:

Zepbound is tirzepatide, a dual GLP-1 and GIP receptor agonist. It acts primarily in the gut and pancreas:

1. GLP-1 receptor activation. Tirzepatide binds to GLP-1 receptors in the stomach, slowing gastric emptying by 60-70%. Food stays in the stomach 3 to 4 hours instead of 90 minutes. The stomach sends satiety signals to the brainstem via the vagus nerve. GLP-1 receptors in the hypothalamus also directly suppress appetite, but this is a secondary effect.

1. GIP receptor activation. Glucose-dependent insulinotropic polypeptide (GIP) receptors in pancreatic beta cells enhance insulin secretion in response to meals. GIP also appears to reduce food intake through central mechanisms not yet fully characterized. The dual agonism produces greater weight loss than GLP-1 agonism alone (semaglutide produces 15% weight loss; tirzepatide produces 21%).

1. Insulin sensitivity improvement. Tirzepatide reduces hepatic glucose production, increases peripheral glucose uptake, and improves beta-cell function. Patients with insulin resistance see metabolic benefits independent of weight loss.

The result is profound appetite suppression, early satiety (feeling full after small meals), and sustained fullness between meals. Zepbound does not act on opioid or dopamine pathways and has no direct effect on food reward.

Head-to-head efficacy: what the indirect comparison shows

No published trial directly compares Contrave and Zepbound. The comparison below uses the primary efficacy endpoints from each drug's phase 3 obesity trials.

Metric	Contrave (COR-I, N=1,742)	Zepbound 15 mg (SURMOUNT-1, N=630)
Mean baseline BMI	36 kg/m²	38 kg/m²
Trial duration	56 weeks	72 weeks
Mean weight loss (%)	5.4% (naltrexone-bupropion) vs 1.3% (placebo)	20.9% (tirzepatide 15 mg) vs 3.1% (placebo)
Patients losing ≥5%	48% vs 17%	89% vs 28%
Patients losing ≥10%	25% vs 7%	73% vs 13%
Patients losing ≥15%	11% vs 2%	57% vs 6%
Discontinuation due to adverse events	22.6%	6.2%

The efficacy difference is substantial. At 1 year, the average Zepbound patient loses roughly 4 times as much weight as the average Contrave patient (21% vs 5%). The proportion of patients achieving clinically meaningful weight loss (≥10%) is 3 times higher with Zepbound (73% vs 25%).

Why the difference matters clinically:

A patient starting at 250 pounds would lose an average of 13.5 pounds on Contrave vs 52 pounds on Zepbound over the first year. For patients with obesity-related comorbidities (type 2 diabetes, hypertension, sleep apnea), the magnitude of weight loss affects whether those conditions improve or resolve.

The COR-BMOD trial (Wadden et al., Lancet 2011) showed that Contrave plus intensive behavioral intervention produced 9.3% weight loss at 56 weeks, narrowing the gap but still well below tirzepatide monotherapy.

The efficacy ceiling:

Contrave's weight loss plateaus at 6 to 9 months. Patients who haven't lost significant weight by month 6 rarely see additional benefit from continuing. Zepbound's weight loss continues through 18 months in extension studies, with some patients losing 25% or more of baseline weight.

The SURMOUNT-3 trial (Aronne et al., JAMA 2024) showed that patients who stopped tirzepatide after 36 weeks regained 14% of body weight over the next 52 weeks, while those who continued lost an additional 5.5%. Contrave has similar weight regain patterns after discontinuation (Greenway et al., Obesity 2010).

Side effect profiles: neuropsychiatric vs gastrointestinal

The side effect profiles are nearly opposite, which makes the choice between medications clearer for patients with specific risk factors.

Contrave's side effect profile:

Side effect	Incidence (Contrave)	Incidence (Placebo)	Notes
Nausea	32.5%	6.7%	Peaks in weeks 1-4, usually resolves by week 8
Headache	17.6%	8.1%	Tension-type; responds to acetaminophen
Constipation	19.2%	7.2%	Bupropion effect; dose-related
Dizziness	9.9%	3.4%	Orthostatic; worse with rapid standing
Insomnia	9.2%	3.1%	Bupropion's dopaminergic effect; take morning dose early
Dry mouth	8.1%	2.3%	Anticholinergic effect; persistent in some patients
Vomiting	10.7%	3.5%	Early titration; improves after week 4
Seizure	0.1%	0.0%	Dose-dependent; contraindicated in seizure disorders
Elevated blood pressure	1.9%	0.4%	Monitor BP monthly during titration

The nausea is centrally mediated (not gastric), usually mild, and resolves faster than GLP-1-induced nausea. The serious risks are seizure (especially at doses above the approved 32 mg/360 mg daily) and blood pressure elevation.

Contrave carries a black-box warning for suicidal thoughts and behaviors due to bupropion. The risk is highest in patients under 24 with major depressive disorder. In obesity trials without psychiatric comorbidity, the incidence was not elevated above placebo.

Zepbound's side effect profile:

Side effect	Incidence (Zepbound 15 mg)	Incidence (Placebo)	Notes
Nausea	33.1%	8.3%	Peaks days 2-5 after dose escalation
Diarrhea	21.2%	7.3%	Osmotic effect from delayed gastric emptying
Vomiting	12.2%	1.7%	Severe in 2-3%; may require dose reduction
Constipation	12.0%	4.5%	Paradoxical; alternates with diarrhea in some patients
Abdominal pain	11.7%	6.2%	Upper quadrant; usually reflux or gastric distension
Decreased appetite	10.3%	2.4%	Therapeutic effect, listed as AE in trials
Fatigue	8.1%	4.2%	Correlates with caloric deficit
Dyspepsia	9.1%	3.8%	Reflux-type symptoms
Injection site reactions	3.8%	1.2%	Mild erythema; rare nodules
Pancreatitis	0.2%	0.0%	Rare but serious; discontinue if suspected
Gallbladder disease	1.5%	0.4%	Risk increases with rapid weight loss

The GI side effects are dose-dependent and usually transient. About 70% of patients with nausea at dose escalation see resolution within 2 weeks at the new dose. Severe persistent nausea occurs in 2 to 3% and is the most common reason for discontinuation.

Zepbound has minimal neuropsychiatric effects. Depression and anxiety rates in SURMOUNT-1 were not elevated above placebo. Insomnia is rare.

The pattern we see in patients switching between the two:

Patients who discontinue Contrave due to side effects most commonly cite persistent nausea (despite it being less severe than GLP-1 nausea), headache, or insomnia. These patients often tolerate Zepbound well because the mechanisms don't overlap.

Patients who discontinue Zepbound due to side effects most commonly cite nausea, vomiting, or reflux. These patients often tolerate Contrave well because it has zero gastric effects.

The side effect profiles are complementary, not overlapping. A patient who fails one due to tolerability has a high probability of tolerating the other.

The patient-type framework: who responds to which medication

The FormBlends Patient-Match Framework for Contrave vs Zepbound organizes decision-making around three patient characteristics: eating pattern, metabolic profile, and risk tolerance.

Contrave-responsive patient type:

• Eating pattern: Binge eating, emotional eating, reward-driven eating, or cravings for specific high-palatability foods (sweets, fried foods). Patients who describe food as comforting or stress-relieving.
• Metabolic profile: Normal or mildly elevated fasting glucose (A1C <6.5%). No significant insulin resistance. BMI 30 to 40 kg/m².
• Risk tolerance: Cannot tolerate nausea or GI side effects due to work or lifestyle. Willing to accept lower weight-loss efficacy in exchange for fewer GI symptoms.
• Psychiatric history: No active seizure disorder, no uncontrolled hypertension, no recent suicidal ideation. May have treated depression or anxiety (bupropion can be therapeutic).

Zepbound-responsive patient type:

• Eating pattern: High baseline appetite, large portion sizes, frequent snacking, or difficulty feeling full. Patients who describe constant hunger or eating until uncomfortably full.
• Metabolic profile: Prediabetes (A1C 5.7-6.4%) or type 2 diabetes. Insulin resistance. BMI 35+ kg/m² or BMI 30+ with metabolic comorbidities.
• Risk tolerance: Willing to manage GI side effects during titration for higher efficacy. Motivated by metabolic improvement (glucose control) in addition to weight loss.
• Psychiatric history: No contraindications. GLP-1 medications do not worsen depression or anxiety in clinical trials.

The overlap zone:

Patients with BMI 32 to 38, no diabetes, and mixed eating patterns (both reward-driven and volume-driven) are candidates for either medication. The choice often comes down to patient preference after reviewing side effect profiles.

What most articles get wrong about Contrave's mechanism

The most common error in published content on Contrave is the claim that naltrexone and bupropion "work synergistically to suppress appetite." This is vague and misleading.

The actual mechanism is specific and non-intuitive: naltrexone does not suppress appetite on its own. In monotherapy trials, naltrexone 50 mg daily produced no significant weight loss compared to placebo (Greenway et al., International Journal of Obesity 2009). Bupropion monotherapy produces modest weight loss (2-3% at 6 months), but the effect plateaus quickly.

The synergy is not additive; it's mechanistic. Bupropion stimulates POMC neurons, which release beta-endorphin as well as alpha-MSH. Beta-endorphin binds to mu-opioid receptors on POMC neurons and inhibits further POMC firing (auto-inhibitory feedback loop). This limits how much bupropion can suppress appetite on its own.

Naltrexone blocks the mu-opioid receptors, preventing the auto-inhibitory feedback. POMC neurons fire more frequently, releasing more alpha-MSH, which binds to MC4 receptors and suppresses appetite more effectively.

The combination produces 5 to 6% weight loss, while bupropion alone produces 2 to 3% and naltrexone alone produces 0%. The synergy is real, but it's a disinhibition mechanism, not simple addition.

This matters clinically because patients sometimes ask whether they can take bupropion (prescribed for depression) and expect weight loss. The answer is: modest weight loss, yes, but far less than the combination. The naltrexone component is essential to the efficacy.

Cost and access: insurance coverage patterns in 2026

Contrave:

• List price: $250 to $300 per month (120 tablets, 30-day supply at maintenance dose)
• Insurance coverage: Covered by 40-50% of commercial plans as of 2026, usually with prior authorization. Medicare Part D does not cover weight-loss medications. Medicaid coverage varies by state (14 states cover Contrave as of 2026).
• Generic availability: Generic naltrexone-bupropion became available in 2023. Generic price is $80 to $150 per month depending on pharmacy.
• Manufacturer savings: Contrave savings card reduces copay to $99/month for commercially insured patients (12-month limit).

Zepbound:

• List price: $1,060 per month (four 2.5 mg pens or one 15 mg pen, depending on dose)
• Insurance coverage: Covered by 60-70% of commercial plans as of 2026 with prior authorization. Medicare Part D does not cover weight-loss medications. Medicaid coverage in 8 states as of 2026.
• Manufacturer savings: Zepbound savings card reduces copay to $550/month for commercially insured patients. Uninsured patients pay $550/month through direct-purchase program (launched Q4 2024).
• Compounded tirzepatide: $299 to $399 per month through telehealth platforms like FormBlends. Not FDA-approved. Available while brand-name tirzepatide remains on the FDA shortage list (status as of April 2026: still listed).

The cost difference is substantial. Patients paying out of pocket typically choose Contrave or compounded tirzepatide. Patients with insurance coverage for Zepbound typically choose Zepbound due to superior efficacy.

The access calculus in 2026:

For patients without insurance coverage, the choice is often between Contrave ($80-150/month generic) and compounded tirzepatide ($299-399/month). The efficacy difference (5% vs 18-20% weight loss) often justifies the cost difference for patients with significant weight to lose or metabolic comorbidities.

For patients with insurance coverage for both, the choice is clinical (eating pattern, metabolic profile, side effect tolerance), not financial.

The combination question: can you take both together?

There is no published data on combining Contrave and Zepbound. The mechanisms do not overlap, so there is no pharmacokinetic interaction expected. The question is whether the combination produces additive efficacy or additive side effects.

Theoretical rationale for combination:

Contrave reduces food reward and cravings centrally. Zepbound reduces appetite and slows gastric emptying peripherally. A patient with both reward-driven eating and high baseline appetite might benefit from dual suppression.

Theoretical concerns:

1. Additive nausea. Both medications cause nausea through different mechanisms (central vs gastric). The combination could produce intolerable nausea.
2. Excessive caloric restriction. The combination might suppress appetite so profoundly that patients cannot meet minimum nutritional needs (1,200 kcal/day for women, 1,500 kcal/day for men).
3. Cost. Paying for both medications simultaneously is prohibitive for most patients.

The clinical reality:

Most providers do not prescribe the combination. The standard approach is to try one medication, assess response at 12 to 16 weeks, and switch to the other if response is inadequate. Sequential monotherapy is safer and more cost-effective than combination therapy.

A small number of patients take bupropion for depression (150-300 mg daily) and add Zepbound for weight loss. This is not the same as the Contrave combination (which uses lower-dose bupropion, 360 mg daily, plus naltrexone). Bupropion monotherapy plus Zepbound is generally well-tolerated, though nausea may be slightly higher than Zepbound alone.

FormBlends position:

We do not recommend combining Contrave and Zepbound without provider supervision. If you are taking bupropion for depression and want to start compounded tirzepatide, discuss the combination with your provider. Most patients tolerate it, but the nausea risk is higher.

Contraindications: who cannot take each medication

Contrave absolute contraindications:

• Uncontrolled hypertension (BP >140/90 despite treatment)
• Seizure disorder or history of seizures
• Anorexia nervosa or bulimia nervosa (current or past)
• Chronic opioid use or acute opioid withdrawal (naltrexone precipitates withdrawal)
• Monoamine oxidase inhibitor (MAOI) use within 14 days
• Pregnancy or breastfeeding
• End-stage renal disease

Contrave relative contraindications (use caution):

• Bipolar disorder (bupropion can precipitate mania)
• Heavy alcohol use (increased seizure risk)
• Hepatic impairment (reduce dose)
• Angle-closure glaucoma
• Age over 75 (increased fall risk from dizziness)

Zepbound absolute contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy (animal studies show fetal harm; discontinue 2 months before conception)
• History of severe hypersensitivity to tirzepatide

Zepbound relative contraindications (use caution):

• History of pancreatitis (recurrence risk is low but present)
• Severe gastroparesis (tirzepatide worsens gastric emptying)
• Diabetic retinopathy (rapid glucose lowering may transiently worsen retinopathy)
• Renal impairment (dose adjustment not required, but monitor for dehydration from GI side effects)
• Age over 75 (limited safety data)

The practical difference:

Contrave's contraindication list is longer and includes common conditions (hypertension, seizure history, opioid use). Zepbound's contraindication list is shorter but includes rare serious conditions (MTC, MEN 2).

Patients with chronic pain on opioid therapy cannot take Contrave (naltrexone blocks opioid receptors and causes withdrawal). These patients can take Zepbound without interaction.

Patients with a family history of thyroid cancer cannot take Zepbound (black-box warning for MTC based on rodent studies, though human cases have not been confirmed). These patients can take Contrave without issue.

The clinical pattern we see in patients switching between the two

Contrave to Zepbound switchers:

The most common reason for switching from Contrave to Zepbound is inadequate weight loss. Patients who lose less than 5% of body weight after 6 months on Contrave are unlikely to see additional benefit from continuing.

The pattern we see: patients lose 8 to 12 pounds in the first 3 months on Contrave, weight loss plateaus, and they switch to compounded tirzepatide. On tirzepatide, they lose an additional 25 to 40 pounds over the next 6 to 9 months.

The transition is usually smooth. Patients stop Contrave and start tirzepatide the following week. There is no washout period required. The side effect profiles do not overlap, so patients who tolerated Contrave usually tolerate tirzepatide (though nausea is common during tirzepatide titration regardless of prior medication history).

Zepbound to Contrave switchers:

The most common reason for switching from Zepbound to Contrave is intolerable GI side effects. Patients who have persistent nausea, vomiting, or reflux despite dose reduction and dietary management sometimes switch to Contrave to maintain some degree of appetite suppression without GI distress.

The pattern we see: patients discontinue tirzepatide after 8 to 16 weeks due to nausea, start Contrave, and tolerate it well. Weight loss on Contrave is modest (5-10 pounds over 6 months), but patients maintain most of the weight they lost on tirzepatide rather than regaining it immediately.

The transition requires managing expectations. Patients who lost 30 pounds on Zepbound in 4 months sometimes expect similar results on Contrave. The efficacy difference is significant, and setting realistic expectations prevents disappointment.

The rebound question:

Patients who switch from Zepbound to Contrave do not experience rebound weight gain if they start Contrave immediately. The appetite suppression from Contrave (though weaker) appears sufficient to prevent the rapid regain seen when patients stop GLP-1 medications without replacement.

Patients who switch from Contrave to Zepbound sometimes experience a "second wind" of weight loss because the mechanisms are complementary. The tirzepatide effect is not blunted by prior Contrave use.

When Contrave is the better choice despite lower efficacy

Scenario 1: Binge eating disorder (BED).

Contrave is FDA-approved for obesity, not BED, but the mechanism directly targets the reward pathways involved in binge eating. A 2013 study (McElroy et al., Obesity 2013) showed that naltrexone-bupropion reduced binge-eating episodes by 47% compared to 19% with placebo, independent of weight loss.

Zepbound reduces appetite and portion sizes but does not specifically target the compulsive, reward-driven aspect of binge eating. Patients with BED often report that Zepbound reduces the volume they eat during binges but does not reduce the frequency or compulsive quality of binge episodes.

For patients with diagnosed or suspected BED, Contrave is often the better first-line choice even though weight loss is lower.

Scenario 2: Patients on chronic opioid therapy who need to continue opioids.

This is a contraindication for Contrave, so Zepbound is the only option. Mentioned here for completeness.

Scenario 3: Patients with severe needle phobia.

Zepbound requires weekly subcutaneous injections. Contrave is oral. Some patients have severe enough needle phobia that they cannot self-inject, even with coaching. For these patients, Contrave is the only viable option unless they can arrange weekly provider-administered injections (impractical for most).

Scenario 4: Patients who cannot tolerate any nausea due to occupation.

Pilots, surgeons, heavy equipment operators, and others in safety-sensitive roles sometimes cannot tolerate even transient nausea. Contrave's nausea is milder and resolves faster than GLP-1 nausea. For these patients, Contrave may be preferable despite lower efficacy.

Scenario 5: Patients with comorbid depression.

Bupropion is an FDA-approved antidepressant. Patients with obesity and comorbid depression may benefit from the dual effect. A 2016 meta-analysis (Khazaal et al., Psychotherapy and Psychosomatics 2016) showed that bupropion improved depression scores independent of weight loss.

Zepbound has no antidepressant effect. For patients with untreated or undertreated depression, Contrave addresses both conditions simultaneously.

The steelman against this section:

A thoughtful clinician might argue that choosing a less effective weight-loss medication (Contrave) for patients with severe obesity and metabolic disease is a disservice, even if the patient has binge-eating patterns or depression. The counterargument is that tirzepatide produces far greater metabolic benefit (A1C reduction, blood pressure reduction, cardiovascular risk reduction) and that these benefits outweigh the theoretical advantage of targeting reward pathways.

The rebuttal: for patients with BMI 30 to 35 without diabetes, the absolute risk reduction from metabolic improvement is small. For these patients, targeting the eating behavior (reward-driven vs appetite-driven) is a reasonable basis for medication selection. For patients with BMI 40+ or diabetes, tirzepatide's superior efficacy usually outweighs behavioral considerations.

FAQ

Which is better for weight loss, Contrave or Zepbound? Zepbound produces significantly greater weight loss. The average patient loses 20-21% of body weight on Zepbound vs 5-6% on Contrave over 1 year. About 73% of Zepbound patients lose at least 10% of body weight compared to 25% on Contrave.

Can you take Contrave and Zepbound together? There is no published safety data on the combination. The mechanisms do not overlap, but both cause nausea and the combination might produce intolerable GI or neuropsychiatric side effects. Most providers recommend sequential monotherapy (try one, switch to the other if needed) rather than combination therapy.

Does Contrave work as well as Zepbound for diabetes? No. Contrave is not FDA-approved for diabetes and does not improve A1C or insulin sensitivity. Zepbound reduces A1C by 2.0 to 2.4 percentage points in patients with type 2 diabetes (SURPASS trials). For patients with diabetes, Zepbound is the clear choice.

Which has worse side effects, Contrave or Zepbound? The side effect profiles are different, not worse or better. Contrave causes more headache, insomnia, and blood pressure elevation. Zepbound causes more nausea, vomiting, and diarrhea. About 23% of Contrave patients discontinue due to side effects vs 6% of Zepbound patients, but this reflects the specific side effects each patient can tolerate.

Is Contrave safer than Zepbound? Both medications have acceptable safety profiles in clinical trials. Contrave carries a black-box warning for suicidal thoughts (due to bupropion) and has seizure risk. Zepbound carries a black-box warning for thyroid C-cell tumors (based on animal data, not confirmed in humans) and has pancreatitis risk. Neither is categorically safer; the risks are different.

How much does Contrave cost compared to Zepbound? Generic Contrave costs $80 to $150 per month. Brand-name Zepbound costs $1,060 per month (or $550 with savings card). Compounded tirzepatide costs $299 to $399 per month. Contrave is significantly less expensive, which makes it the default choice for uninsured patients who cannot afford GLP-1 medications.

Can you switch from Contrave to Zepbound without a break? Yes. There is no required washout period. Patients can stop Contrave and start Zepbound the following week. The mechanisms do not interact, so there is no risk of drug-drug interaction during the transition.

Does Contrave cause the same nausea as Zepbound? Contrave causes nausea in about 33% of patients, similar to Zepbound's rate. However, Contrave's nausea is centrally mediated (brain-based), usually milder, and resolves faster (within 4 to 8 weeks). Zepbound's nausea is gastric, often more severe, and can persist through dose escalations.

Which medication is better for emotional eating? Contrave. It acts on brain reward pathways and reduces the rewarding value of food, which is the mechanism underlying emotional eating and binge eating. Zepbound reduces appetite but does not specifically target reward-driven eating behavior.

Do you need a prescription for both Contrave and Zepbound? Yes. Both are prescription medications. Contrave is a Schedule IV controlled substance (due to bupropion's potential for misuse). Zepbound is not controlled but requires a prescription. Compounded tirzepatide also requires a prescription from a licensed provider.

Can you take Contrave if you have high blood pressure? Contrave can raise blood pressure in some patients (1.9% incidence in trials). It is contraindicated in uncontrolled hypertension (BP >140/90). If your blood pressure is controlled on medication, you can take Contrave with monthly BP monitoring. If BP rises above 140/90, discontinue Contrave.

Does Zepbound work better than Contrave for appetite suppression? Yes. Zepbound produces more profound appetite suppression. Patients on Zepbound report feeling full after small meals and staying full for hours. Contrave reduces cravings and food reward but does not produce the same degree of appetite suppression or early satiety.

How long does it take to see results with Contrave vs Zepbound? Contrave patients typically lose 5 to 8 pounds in the first 3 months, with weight loss plateauing at 6 to 9 months. Zepbound patients lose 10 to 15 pounds in the first 3 months and continue losing weight through 12 to 18 months. Zepbound produces faster and more sustained weight loss.

Can you drink alcohol on Contrave or Zepbound? Contrave carries a warning about alcohol use. Heavy drinking increases seizure risk with bupropion. Moderate alcohol (1 to 2 drinks per occasion) is generally tolerated but may worsen dizziness or nausea. Zepbound has no specific alcohol interaction, but alcohol can worsen nausea and reflux. Both medications work better with limited alcohol intake.

Which medication is covered by more insurance plans? Zepbound has slightly higher coverage rates (60-70% of commercial plans) compared to Contrave (40-50%). However, both require prior authorization, and coverage varies widely by plan. Medicare Part D does not cover either medication for weight loss.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010.
3. Apovian CM et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013.
4. Wadden TA et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011.
5. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
6. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
8. McElroy SL et al. Naltrexone SR/Bupropion SR Reduces Binge Eating Behavior in Subjects with Binge Eating Disorder. Obesity. 2013.
9. Greenway FL et al. Naltrexone for obesity: an evidence-based review. International Journal of Obesity. 2009.
10. Khazaal Y et al. Does bupropion improve depression in patients with substance use disorder? A systematic review and meta-analysis. Psychotherapy and Psychosomatics. 2016.
11. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
12. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
13. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Contrave is a registered trademark of Currax Pharmaceuticals LLC. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.